Trial Profile
Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2018
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 29 Apr 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 03 Mar 2015 Status changed from not yet recruiting to active, no longer recruiting, according University Hospital Medical Information Network - Japan
- 10 Jul 2014 New trial record